← Back to Search

Prevent Maternal Mortality using Mobile technology (PM3) for Postpartum

N/A

Waitlist Available

Led By Natalie Hernandez, PhD

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, month 3, month 6 and month 12

Awards & highlights

Study Summary

This trial is looking at using a mobile app to help improve postpartum care for black women in rural areas, who are at a higher risk for maternal morbidity and mortality.

Eligible Conditions

Postpartum

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, month 3, month 6 and month 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, month 3, month 6 and month 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 3, month 6 and month 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of completion of postpartum healthcare visit ( Healthcare Resource utilization)

Secondary outcome measures

Adverse Childhood Experiences (ACEs) questionnaire

Appraisal of self-care agency Scale-Revised (ASAS-R)

Changes in Blood pressure

+15 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Mother Using PM3 InterventionExperimental Treatment1 Intervention

Participants in this group will be using the PM3 intervention. PM3 is a maternal mortality prevention and optimal reproductive health promotion mobile app created based on formative work with Black women to ultimately increase postpartum comorbidity self-management, promote timely provider notification of postpartum-related complications, and ensure access to social support and community resources.

Group II: Mothers following Standard of CareActive Control1 Intervention

Participants randomized to this group will receive standard of Care for Postpartum. The standard of care control condition will be what women would typically get at hospital discharge (typically an Electronic Medical Record (EMR) generated document; a non-standardized, generalized brief review of how to care for self and the baby).

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor

1,636 Previous Clinical Trials

2,560,273 Total Patients Enrolled

Natalie Hernandez, PhDPrincipal InvestigatorAssistant Professor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the requisite criteria for individuals to enroll in this investigation?

"Those wishing to be admitted into this clinical trial must have experienced maternal death and are between the ages of 18 and 45. A total of 300 participants will be accepted."

Answered by AI

Is the cutoff age for this experiment less than forty years old?

"The eligibility parameters for this trial specify that the youngest participant must be 18 and the oldest can be no more than 45."

Answered by AI

How many participants are currently involved in this clinical experiment?

"That is indeed the case. According to clinicaltrials.gov, this trial was inaugurated on March 22nd 2022 and has been recruiting since then. The researchers are hoping to enrol 300 individuals between two different sites."

Answered by AI

Are there still openings for enrolment in this experiment?

"As per information available on clinicaltrials.gov, this experiment is presently recruiting patients. This trial was initially unveiled on March 22nd 2022 and had its most recent update occur on April 15th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Prevent Maternal Mortality Using Mobile Technology

Natalie Hernandez 2022. "Prevent Maternal Mortality Using Mobile Technology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05339867.